Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.4B
$42.25
▲ +0.93%
P/E
13.59
Mkt Cap
$2.4B
52-Wk Range
$25.52–$43.49
52-Week Range
$25.52 - $43.49
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 17.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- FDA-approved first-in-class treatment for narcolepsy with differentiated mechanism of action
- Specialized focus on rare neurological disorders with limited competitive alternatives
- Established commercial infrastructure and market presence for WAKIX distribution
- Orphan drug designation providing regulatory exclusivity and market protection
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Expanding WAKIX market penetration and patient awareness in narcolepsy treatment
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+30.4% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying HRMY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of $1.28 vs $0.96 consensus (+33.9% surprise). Revenue of $261.3M vs $250.8M expected (+4.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+33.9%
Revenue trend · last 8Q
—
+20%
+19%
+16%
+29%
+21%
+17%
+30%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$186.0M
$201.3M
$184.7M
$200.5M
$239.5M
$243.8M
$215.4M
$261.3M
Margins · last 8Q
Gross
75.8%
Operating
34.2%
Profit
28.9%
Wall Street consensus
4 analysts · 25% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
25%
Hold
75%
Sell
0%
Median Price Target
—
Latest: Deutsche Bank · Aug 5, 2026
vs Industry
How HRMY stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related